These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 32267794)
1. Novel antithrombotic regimen in patients with ischemic heart disease and peripheral arterial disease: can we identify those who derive the highest benefit? Mahtta D; Virani SS J Med Econ; 2020 Jul; 23(7):670-672. PubMed ID: 32267794 [No Abstract] [Full Text] [Related]
2. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. Califf RM; Mark DB Am Heart J; 1997 Nov; 134(5 Pt 2):S88-96. PubMed ID: 9396640 [No Abstract] [Full Text] [Related]
5. Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none. Tangelder MJ; van Hattum ES Thromb Haemost; 2010 Aug; 104(2):196-9. PubMed ID: 20508897 [No Abstract] [Full Text] [Related]
6. CLINICAL AND PHARMACEUTICAL ASPECTS OF THE USE OF ANTITHROMBOTIC DRUGS IN PATIENTS SUFFERING FROM ISCHEMIC HEART DISEASE (REVIEW). Zhunussov Y Georgian Med News; 2016 Feb; (251):32-9. PubMed ID: 27001783 [TBL] [Abstract][Full Text] [Related]
7. Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease. Schindewolf M; Beyer-Westendorf J; Balradj J; Bowrin K; Huelsebeck M; Briere JB Angiology; 2020 Oct; 71(9):773-790. PubMed ID: 32638610 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of cilostazol in the treatment of peripheral arterial obstruction. Rybak Z Pol Arch Med Wewn; 2015; 125(3):117-9. PubMed ID: 25599245 [No Abstract] [Full Text] [Related]
9. [Mechanism of action and clinical use of ticlopidine]. Kirichenko AA Kardiologiia; 2006; 46(4):75-80. PubMed ID: 16710210 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic therapy in the elderly. Capodanno D; Angiolillo DJ J Am Coll Cardiol; 2010 Nov; 56(21):1683-92. PubMed ID: 21070918 [TBL] [Abstract][Full Text] [Related]
13. [Antithrombotic therapy in acute coronary syndrome]. Chazov EI; Panchenko EP Ter Arkh; 2000; 72(3):65-75. PubMed ID: 10776658 [No Abstract] [Full Text] [Related]
14. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113 [TBL] [Abstract][Full Text] [Related]
15. Antithrombotic treatment in peripheral artery disease. Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765 [TBL] [Abstract][Full Text] [Related]
16. [Proposal for a diagnostic and therapeutic care pathway of the Piedmont Region on lipid-lowering and antithrombotic treatment in patients with peripheral arterial disease]. Patti G; Varbella F; Gaggiano A; Mennuni M; Annibali G; Celentani D; Del Nevo F; Piazza S; Musumeci G G Ital Cardiol (Rome); 2023 May; 24(5):344-354. PubMed ID: 37102347 [TBL] [Abstract][Full Text] [Related]
18. Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. Ward R; Long C; Patel MR; Jones WS Clin Cardiol; 2018 Jan; 41(1):137-143. PubMed ID: 29355992 [TBL] [Abstract][Full Text] [Related]
19. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630 [TBL] [Abstract][Full Text] [Related]
20. Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities? Bodansky DM; Allon IR; Apostolakis S; Lip GY Int J Clin Pract; 2015 Feb; 69(2):162-8. PubMed ID: 24898695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]